Expert consensus on the management of chronic lymphocytic leukaemia in Asia

In recent years, considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia (CLL) due to the availability of new potent drugs. However, the majority of data on CLL were derived from Western populations, with limited studies and guidelines on the management of CLL...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental medicine 2023-10, Vol.23 (6), p.2895-2907
Main Authors: Tse, Eric, Kwong, Yok Lam, Goh, Yeow Tee, Bee, Ping Chong, Ng, Soo Chin, Tan, Daryl, Caguioa, Priscilla, Nghia, Huynh, Dumagay, Teresita, Norasetthada, Lalita, Chuncharunee, Suporn, Radhakrishnan, Vivek, Bagal, Bhausaheb, Atmakusuma, Tubagus Djumhana, Mulansari, Nadia Ayu
Format: Article
Language:English
Subjects:
Chronic lymphocytic leukemia
Correspondence
Hematology
Internal Medicine
Literature reviews
Medicine
Medicine & Public Health
Oncology
Population studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent years, considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia (CLL) due to the availability of new potent drugs. However, the majority of data on CLL were derived from Western populations, with limited studies and guidelines on the management of CLL from an Asian population perspective. This consensus guideline aims to understand treatment challenges and suggest appropriate management approaches for CLL in the Asian population and other countries with a similar socio-economic profile. The following recommendations are based on a consensus by experts and an extensive literature review and contribute towards uniform patient care in Asia.
ISSN:1591-9528
1591-8890
1591-9528
DOI:10.1007/s10238-023-01007-2